Medicare Advantage insurtech company Devoted Health secures $175M
2024-01-02
Preview
来源: mobihealthnews
Photo: Luis Alvarez/Getty Images
Tech-enabled Medicare Advantage company Devoted Health announced it scored $175 million in Series E funding at the end of 2023.
Venture capital companies Fearless Ventures, Highbury Holdings, Stardust Equity, GIC, Maverick Ventures and The Space Between led the round.
Andreessen Horowitz, Emerson Collective, Socium Ventures, The Private Shares Fund, and affiliated funds, General Catalyst, F-Prime Capital Partners and GreatPoint Ventures also participated in the round.
WHAT THEY DO
The insurtech company offers a stack of healthcare services to older adults, including Medicare Advantage health plans, partnerships with providers, and its in-house virtual and at-home care provider, Devoted Medical.
The company was founded in 2017 by Todd Park, who previously cofounded Athenahealth and Castlight Health, and his brother Ed Park, who held top positions at Athenahealth.
"In a healthcare system that isn’t always accessible or easy to navigate, we at Devoted Health are profoundly honored to provide each member with the same quality of care and service we’d want for our own families," Ed Park, CEO of Devoted Health, said in a statement.
"It’s deeply gratifying to have so many others believe in the promise of our model, and we’re very excited to bring the love and world-class care that is Devoted to more and more Americans,"
MARKET SNAPSHOT
In 2021, Devoted Health scored $1.15 billion in Series D funding to support nationwide expansion. The company said in a statement that as of December 2023, it served more than 140,000 members in 299 counties across 13 states in the U.S.
In October, Devoted Health was one of 31 contracts that received a five-star rating from the Centers for Medicare and Medicaid Services' Medicare Advantage, Part C and Medicare Part D Star Ratings, which rate MA plans by the quality of health and drug services received by consumers.
Tags: Devoted Health, Medicare Advantage
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
-药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。